Biotech News
Vanda and AnaptysBio Finalise Exclusive Licence Agreement for Imsidolimab in Rare Skin Disease
Vanda Pharmaceuticals has signed an exclusive, global licence agreement with AnaptysBio for the development and commercialisation of imsidolimab, an IL-36R antagonist monoclonal antibody. The agreement grants Vanda full rights to imsidolimab, which has successfully completed two registration-enabling Phase 3 trials—GEMINI-1
4 February 2025